Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
29.88 USD | +3.27% | +2.52% | -6.69% |
Apr. 11 | Harmony Biosciences, Bioprojet Enter Licensing Deal for Sleep Disorder Therapy | MT |
Apr. 03 | Harmony Biosciences Begins Phase 3 Trial of Pitolisant to Treat Prader-Willi Syndrome Symptoms | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.69% | 1.64B | |
+26.01% | 653B | |
+26.31% | 556B | |
-6.50% | 354B | |
+20.52% | 331B | |
+5.55% | 296B | |
+12.70% | 233B | |
+5.53% | 201B | |
-9.65% | 193B | |
-5.73% | 144B |
- Stock Market
- Equities
- HRMY Stock
- News Harmony Biosciences Holdings, Inc.
- Harmony Biosciences to Conduct Phase 3 Trial of Pitolisant for Treatment of Idiopathic Hypersomnia